New drug combo aims to shrink Hard-to-Treat neuroendocrine tumors

NCT ID NCT04086485

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 13 times

Summary

This study tests whether combining Lutathera (a radioactive drug given by IV) with Olaparib (a pill) can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several cycles. The goal is to find a safe dose and see if the tumors respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutathera (a radioactive drug) and Olaparib (a pill)
What this could lead to: If it works, this combination could offer a new way to shrink these rare tumors and slow their growth.
What could go wrong: This is an early-phase trial with only 56 people, so it is not yet known if the combination is safe or effective. Side effects from the radiation and drug are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATICO TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoid tumor digestive system neuroendocrine tumor, grade 1/2 neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROENTEROPANCREATICO TUMORS NEUROENDOCRINE NEOPLASMS NEUROENDOCRINE TUMORS

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.